0001144204-17-016366.txt : 20170324 0001144204-17-016366.hdr.sgml : 20170324 20170324071330 ACCESSION NUMBER: 0001144204-17-016366 CONFORMED SUBMISSION TYPE: 8-A12B/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170324 DATE AS OF CHANGE: 20170324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SINOVAC BIOTECH LTD CENTRAL INDEX KEY: 0001084201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: B9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-A12B/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-32371 FILM NUMBER: 17711165 BUSINESS ADDRESS: STREET 1: 39 SHANGDI XI ROAD STREET 2: HAIDIAN DISTRICT CITY: BEIJING STATE: F4 ZIP: 100085 BUSINESS PHONE: 86-10-82890088 MAIL ADDRESS: STREET 1: 39 SHANGDI XI ROAD STREET 2: HAIDIAN DISTRICT CITY: BEIJING STATE: F4 ZIP: 100085 FORMER COMPANY: FORMER CONFORMED NAME: NET FORCE SYSTEMS INC DATE OF NAME CHANGE: 19991110 8-A12B/A 1 v462588_8a12ba.htm FORM 8-A12B/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

 

FORM 8-A

Amendment No. 1

 

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

SINOVAC BIOTECH LTD.

(Exact name of registrant as specified in its charter)

 

 

Antigua, West Indies   Not Applicable
(State or other jurisdiction   (I.R.S. Employer Identification
of incorporation or organization)   Number)

 

 

No. 39 Shangdi Xi Road,

Haidian District, Beijing 100085

People’s Republic of China

  

Not Applicable

(Address of Principal Executive Offices)   (Zip Code)

 

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

___________________________________

  

Name of each exchange on which each

class is to be registered

__________________________________

Preferred Share Purchase Rights   The NASDAQ Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. þ

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨

 

Securities Act registration statement file number to which this form relates: Not applicable (if applicable)

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 

 

Item 1. Description of Registrant’s Securities to be Registered

 

Reference is hereby made to the Registration Statement on Form 8-A filed by Sinovac Biotech Ltd., an Antigua and Barbuda company (the “Company”), with the Securities and Exchange Commission (the “SEC”) on March 29, 2016 (the “Registration Statement”), relating to the Rights Agreement, dated as of March 28, 2016 (the “Rights Agreement”) between the Company and Pacific Stock Transfer Company, as Rights Agent. Such Registration Statement is hereby incorporated herein by reference.

 

On March 24, 2017, the Company entered into an amendment to the Rights Agreement (the “Amendment”), to extend the expiration date of the rights contained therein from March 27, 2017 to March 27, 2018.

 

The foregoing summary of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 4.1 to the Company’s Form 6-K, filed with the SEC on March 24, 2017, and is incorporated herein by reference. A copy of the Rights Agreement and a summary of its material terms were filed with the SEC on Form 6-K on March 29, 2016 (incorporated herein by reference by Exhibit 4.2).

 

Item 2. Exhibits

 

1.Amendment to Rights Agreement, dated as of March 24, 2017, between Sinovac Biotech Ltd. and Pacific Stock Transfer Company, as Rights Agent (incorporated by reference to Exhibit 4.1 of the Report on Form 6-K dated March 24, 2017 of Sinovac Biotech Ltd.)

 

2.Rights Agreement, dated as of March 28, 2016, between Sinovac Biotech Ltd. and Pacific Stock Transfer Company, as Rights Agent, which includes the Form of Certificate of Designations of Series A Junior Participating Preferred Shares as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (incorporated by reference to Exhibit 4.1 of the Report on Form 6-K dated March 29, 2016 of Sinovac Biotech Ltd.)

 

3.Press Release of Sinovac Biotech Ltd., dated March 24, 2017 (incorporated by reference to Exhibit 99.1 of the Report on Form 6-K dated March 24, 2017 of Sinovac Biotech Ltd.)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

  SINOVAC BIOTECH LTD.  
        
        
        
  By:  /s/ Nan Wang  
     Name: Nan Wang  
     Title: Chief Financial Officer  

 

 

Date: March 24, 2017